Fig. 6

Inhibition of complex I using BAY 87-2243 in combination with vemurafenib attenuated melanoma tumor growth in vivo. a Nude mice were xenotransplanted with 3 × 10⁶ SK-MEL-28 (50 % matrigel) human melanoma cells (n = 10 per group). Mice were treated orally (p.o.) with vemurafenib (20 mg/kg, twice a day) or for combination studies with vemurafenib (20 mg/kg, twice a day) and BAY 87-2243 (9 mg/kg, once a day). Tumor volume was measured. b Relative tumor size (%) of individual SK-MEL-28 xenograft tumors (tumor area at study end × 100 / tumor area at study begin). Partial regression, <70 % (tumor size at study end > 30 % smaller than original tumor size at study start); stable disease, 70–120 % (tumor size between 30 % smaller and 20 % bigger of original size); progressive disease, >120 % (tumor size at study end > 20 % bigger than original size). c Tumor weights of individual SK-MEL-28 xenograft tumors. d Body weights of mice (n = 10) bearing human SK-MEL-28 xenografts treated orally (p.o.) once daily with vehicle (ethanol/solutol/water = 10:40:50), or with vemurafenib (20 mg/kg, twice a day), or for combination studies with vemurafenib (20 mg/kg, twice a day) and BAY 87-2243 (9 mg/kg, once a day). Data are represented as the mean ± SD. *p < 0.05